Date:10/21/2010

ended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.CONTACT:Investor Relations:

Company Contact:Tim Ryan

Molly HendersonThe Shoreham Group

Chief Business and Financial Officer80 Eighth Ave, Ste 1107

500 Linden OaksNew York, NY 10011

Rochester, New York 14625+1 212 242 7777 Direct

+1 585 249 6231tryan@shorehamgroupllc.com
'/>"/>

SOURCE VirtualScopics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. VirtualScopics Revenues Hit Another Quarterly Record
2. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
3. VirtualScopics and ABX-CRO Collaborate to Enhance Global Molecular Imaging Offerings
4. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
5. VirtualScopics Added to Russell Microcap Index
6. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
7. VirtualScopics Receives Issuance in Japan of Prominent Patent
8. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
9. VirtualScopics to Present at the 8th Annual Bio Investor Forum
10. VirtualScopics Project Balance Exceeds a Record $35 Million
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial